Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04517682 · ClinicalTrials.gov registry record
COVID-19 and SARS-CoV-2 Detection in Saliva
A clinical trial of RNA Virus Infections, sponsored by Ambry Genetics.
- Completed
- Registry status
- 67
- Enrollment target
- 1
- Study location
NCT04517682: Completed study of RNA Virus Infections, sponsored by Ambry Genetics.
NCT04517682 is a study of RNA Virus Infections that has completed, run by Ambry Genetics. The registered enrollment target is 67 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04517682, a study of RNA Virus Infections, has completed, sponsored by Ambry Genetics.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.
Primary Outcome
TaqPath RT-PCR assay performed on saliva compared to TaqPath RT-PCR performed on nasopharyngeal samples for assay accuracy, concordance, reproducibility/precision, analytical sensitivity and analytical specificity.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST RT-PCR
Study Locations (1)
California
- Ambry Genetics - Aliso Viejo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-05-21 |
| Est. Completion | 2021-08-05 |
What the finished NCT04517682 record still lists
NCT04517682 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 1 condition, with RNA Virus Infections appearing as the primary indexed condition, and to 1 intervention - of which RT-PCR is the first listed.
NCT04517682 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04517682 about?
NCT04517682 is a clinical study titled "COVID-19 and SARS-CoV-2 Detection in Saliva". This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.
What is the current status of trial NCT04517682?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2020-05-21. Estimated completion is 2021-08-05.
What conditions does trial NCT04517682 study?
This clinical trial studies the following conditions: RNA Virus Infections.
What interventions are being tested in trial NCT04517682?
The interventions under investigation include: RT-PCR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04517682?
This trial is sponsored by Ambry Genetics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04517682 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RNA Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI